Study Start-Up

Sujay Jadhav, global vice president, study start-up, Oracle Health Sciences, spoke with ACT on how study start-up has been impacted by the pandemic and what its future holds beyond COVID.

With a major wave of post-COVID trial starts on the horizon, the industry’s need to accelerate clinical research through study start-up is intensifying.

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.

Why? Because more often than not, you do not want to accrue only one participant to a clinical trial.

Despite the substantial difficulties associated with orphan drug trial recruitment, this segment of the drug development market is booming.